APA (7th ed.) Citation

R, M., BC, A., MM, H., S, O., S, B., DW, D., . . . RHJ, M. (2025). Bioequivalence of alternative pembrolizumab dosing regimens: Current practice and future perspectives. Cancer communications (London, England), 45(4), 471. https://doi.org/10.1002/cac2.12661

Chicago Style (17th ed.) Citation

R, Malmberg, et al. "Bioequivalence of Alternative Pembrolizumab Dosing Regimens: Current Practice and Future Perspectives." Cancer Communications (London, England) 45, no. 4 (2025): 471. https://doi.org/10.1002/cac2.12661.

MLA (9th ed.) Citation

R, Malmberg, et al. "Bioequivalence of Alternative Pembrolizumab Dosing Regimens: Current Practice and Future Perspectives." Cancer Communications (London, England), vol. 45, no. 4, 2025, p. 471, https://doi.org/10.1002/cac2.12661.